Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 8
1997 10
1998 10
1999 14
2000 5
2001 8
2002 3
2003 3
2004 5
2005 2
2006 2
2007 3
2008 8
2009 8
2010 2
2011 1
2012 1
2013 2
2014 1
2016 1
2017 3
2018 4
2019 1
2020 4
2021 5
2022 5
2023 2
2025 5
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
The Safety and Efficacy of Growth Hormone Secretagogues.
Sigalos JT, Pastuszak AW. Sigalos JT, et al. Sex Med Rev. 2018 Jan;6(1):45-53. doi: 10.1016/j.sxmr.2017.02.004. Epub 2017 Apr 8. Sex Med Rev. 2018. PMID: 28400207 Free PMC article. Review.
AIM: To review the literature on GH secretagogues (GHSs), which include GH-releasing peptides and the orally available small-molecule drug ibutamoren mesylate. METHODS: Review of clinical studies on the safety and efficacy of GHSs in human subjects. ...
AIM: To review the literature on GH secretagogues (GHSs), which include GH-releasing peptides and the orally available small-molecule drug …
Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control.
Philip M, Karakka Kal AK, Subhahar MB, Karatt TK, Mathew B, Koshy SA. Philip M, et al. Rapid Commun Mass Spectrom. 2022 Sep 30;36(18):e9337. doi: 10.1002/rcm.9337. Rapid Commun Mass Spectrom. 2022. PMID: 35716382
RESULTS: In this study, 22 metabolites of ibutamoren were identified (17 phase I and 5 phase II). Oxidation of ibutamoren leads to hydroxylated metabolites (mono and di). ...The major metabolites can be detected up to 96 hours after a single dose, and ibutamoren …
RESULTS: In this study, 22 metabolites of ibutamoren were identified (17 phase I and 5 phase II). Oxidation of ibutamoren lead …
Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren.
Liu H, Sun D, Myasnikov A, Damian M, Baneres JL, Sun J, Zhang C. Liu H, et al. Nat Commun. 2021 Nov 4;12(1):6410. doi: 10.1038/s41467-021-26735-5. Nat Commun. 2021. PMID: 34737341 Free PMC article.
Here, we report high-resolution cryo-EM structures of the GHSR-G(i) signaling complex with ghrelin and the non-peptide agonist ibutamoren as an investigational new drug. Our structures together with mutagenesis data reveal the molecular basis for the binding of ghrelin and …
Here, we report high-resolution cryo-EM structures of the GHSR-G(i) signaling complex with ghrelin and the non-peptide agonist ibutamoren …
Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles.
Yoon YS, Jang Y, Hoenen T, Shin H, Lee Y, Kim M. Yoon YS, et al. BMB Rep. 2020 Mar;53(3):166-171. doi: 10.5483/BMBRep.2020.53.3.175. BMB Rep. 2020. PMID: 31964466 Free PMC article.
The third group included sertindole, raloxifene, and ibutamoren showing prominent antiviral effects in cells. They downregulated the expression of viral proteins, including the VP40 matrix protein and the envelope glycoprotein. They also reduced the amount of EBOV-derived …
The third group included sertindole, raloxifene, and ibutamoren showing prominent antiviral effects in cells. They downregulated the …
Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren.
Philip M, Karakka Kal AK, Subhahar MB, Perwad Z, Karatt TK. Philip M, et al. Rapid Commun Mass Spectrom. 2021 Dec 15;35(23):e9201. doi: 10.1002/rcm.9201. Rapid Commun Mass Spectrom. 2021. PMID: 34542924
RESULTS: A total of 32 metabolites for ibutamoren (20 phase I and 12 phase II) were detected. The important findings of the current research are as follows: (1) the growth hormone secretagogue ibutamoren was prone to oxidation, resulting in corresponding hydroxylate …
RESULTS: A total of 32 metabolites for ibutamoren (20 phase I and 12 phase II) were detected. The important findings of the current r …
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Sinha DK, et al. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. Transl Androl Urol. 2020. PMID: 32257855 Free PMC article. Review.
The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. All are potent GH and IGF-1 stimulators that can significantly improve body composition while ameliorating specific hypogonadal symptoms inclu …
The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. Al …
Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.
Abdul Ghafoor N, Rasuli S, Tanriverdi Ö, Yildiz A. Abdul Ghafoor N, et al. Basic Clin Pharmacol Toxicol. 2025 Jan;136(1):e14111. doi: 10.1111/bcpt.14111. Basic Clin Pharmacol Toxicol. 2025. PMID: 39668330
This study explored the potential of ibutamoren (IBU) as a novel inhibitor of MDM2. In silico analyses utilizing molecular modelling revealed that IBU has a low IC(50) for MDM2 inhibition and favourably binds to the p53-binding pocket of MDM2. ...
This study explored the potential of ibutamoren (IBU) as a novel inhibitor of MDM2. In silico analyses utilizing molecular modelling …
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G. Codner E, et al. Clin Pharmacol Ther. 2001 Jul;70(1):91-8. doi: 10.1067/mcp.2001.116514. Clin Pharmacol Ther. 2001. PMID: 11452249 Clinical Trial.
On day 15 all patients received an 0.8-mg/kg dose of ibutamoren mesylate. Patients in groups I and II were studied first to assess safety at the low dose before advancement to the high dose. ...There was no change in serum prolactin, glucose, triiodothyronine, thyroxine, t …
On day 15 all patients received an 0.8-mg/kg dose of ibutamoren mesylate. Patients in groups I and II were studied first to assess sa …
117 results